Foghorn Therapeutics, Inc. (FHTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.92+1.03%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Warn: Management is running behind on a stated commitment.
Foghorn Therapeutics is advancing clinical trials to build future growth. Operating losses improved from -$26.6M to -$21.6M recently. Cash burn remains steady near -$25M per quarter. The stock gained over 60% in the past month on positive earnings beats.
The company remains unprofitable with negative EPS expected through 2027. Cash burn is still high and progress on clinical programs is behind schedule. Revenue growth is uncertain and losses may continue.
The price is about 6% above our fair value near $5.6. Analysts expect about 21% revenue growth next year. Our view is aligned but cautious given the ongoing losses and development risks.
Breaks if: cash burn exceeds -$25.3M per quarter
Manage cash resources prudently to extend runway into the first half of 2028, balancing R&D investment and operating expenses.
Management has stated disciplined cash management as a priority in 3 of last 3 quarters. Cash, cash equivalents, and marketable securities increased from $158.9 million in 2025-Q4 to $183.6 million in 2026-Q1, then decreased to $167.6 million in 2026-Q2. The company maintains a cash runway into the first half of 2028, consistent with management's stated goal, indicating delivery on cash discipline.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state is cautious, reflecting a recent recovery in financial performance but with ongoing risks and uncertainties.
The market appears to have priced in a low level of fragility, with the valuation showing that FHTX is considered cheap compared to its peers. There is an expectations gap indicating that the market may not fully anticipate future performance improvements.
Management is focused on advancing clinical development programs and maintaining disciplined cash management. Recent financial performance has improved, but risks remain elevated, particularly in a high-miss-rate industry.
The long-term thesis hinges on the company's ability to advance its clinical programs and the broader healthcare sector's performance. Key factors include potential guidance changes and the impact of economic conditions on the sector.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings beat is a positive factor. However, a sharp drop in the stock price suggests the market may be repricing the thesis. This price movement raises concerns about the company's outlook.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Strong balance sheet with cash of approximately $168 million; cash runway into first half of 2028.”
“Cash, cash equivalents, and marketable securities of approximately $184 million; cash runway into first half of 2028.”
“Cash, cash equivalents, and marketable securities of approximately $159 million; cash runway into first half of 2028.”
Breaks if: progress score falls below 7.1
Progress the Phase 1 dose-escalation trial of FHD-909 in SMARCA4-mutant NSCLC and advance selective CBP, EP300, and ARID1B degrader programs toward INDs in 2027.
Stated as a priority in 3 of last 3 quarters. The Phase 1 trial of FHD-909 in SMARCA4-mutant NSCLC is progressing on schedule since dosing began in 2024-Q4. Selective CBP and EP300 degrader programs are advancing with INDs targeted in 2027, and ARID1B degrader is moving toward in vivo proof of concept in 2026. Management consistently emphasizes clinical advancement and pipeline expansion, and the trajectory is delivering as planned.
“FHD-909 Phase 1 dose-escalation trial advancing as planned; IND targeted in 2027 for EP300 and immunology programs.”
“Phase 1 trial on track; IND-enabling studies anticipated in 2026 with expected IND in 2027 for CBP and EP300 degraders.”
“Phase 1 trial progressing well; advancing selective EP300 and CBP degraders; ARID1B degrader advancing toward in vivo proof of concept.”
Breaks if: operating loss worsens beyond -$21.6M
Manage cash resources prudently to extend runway into the first half of 2028, balancing R&D investment and operating expenses.
Management has stated disciplined cash management as a priority in 3 of last 3 quarters. Cash, cash equivalents, and marketable securities increased from $158.9 million in 2025-Q4 to $183.6 million in 2026-Q1, then decreased to $167.6 million in 2026-Q2. The company maintains a cash runway into the first half of 2028, consistent with management's stated goal, indicating delivery on cash discipline.
“Strong balance sheet with cash of approximately $168 million; cash runway into first half of 2028.”
“Cash, cash equivalents, and marketable securities of approximately $184 million; cash runway into first half of 2028.”
“Cash, cash equivalents, and marketable securities of approximately $159 million; cash runway into first half of 2028.”
Overall, FHTX presents a complex picture with both opportunities and risks over the next 1 to 3 years. Not investment advice.